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Received December 15, 2015; accepted June 30, 2016AbstractBackground: In the general population, prostate adenocarcinoma affects predominately older men. If fact, most current guidelines suggest that
males over the age of 50 years should undergo prostate cancer screening. However, the clinical behavior and prognosis of prostate cancer in
young adults is not well defined. The aim of this study was to evaluate the clinical behavior, pathological characteristics, and prognosis of
prostate cancer in young adults.
Methods: We retrospectively reviewed the records of young patients (age, 50 years) in our hospital with prostate adenocarcinoma between
1997 and 2013. We compared data including initial presentation, cancer cell type, Gleason score, disease stage, prostate-specific antigen (PSA)
level, prostate volume, treatment, and survival between patients both younger and older than 50 years. Data were analyzed using the
KaplaneMeier method to assess survival.
Results: Twenty-six patients were enrolled in our study, accounting for 0.55% of all patients with a diagnosis of prostate cancer at our facility.
All 26 patients had a pathology diagnosis of adenocarcinoma, with a mean age on diagnosis of 46.8 ± 2.8 years (range, 39e50 years). On initial
presentation, patients older than 50 years more frequently displayed lower urinary tract symptoms (LUTS) than younger patients (62.3% vs.
30.4%, p¼ 0.008). There was no statistical difference in histological grade, disease stage, PSA level, overall survival, and biochemical-free
survival between the two groups.
Conclusion: The result of our investigation indicated that prostate adenocarcinoma patients younger than 50 years had similar histological grade,
disease stage, PSA level, overall survival, and biochemical-free survival as the older population. However, patients younger than 50 years with
prostate cancer less frequently showed initial symptoms of LUTS.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate adenocarcinoma is a condition that primarily af-
fects older men. Males younger than 50 years account for
approximately 1% of all patients diagnosed with prostate
adenocarcinoma.1 The current literature suggests that clinical
characteristics and prognosis of prostate cancer in young
adults are conflicting and remain unresolved. Some observerssevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Table 1
Characteristics and univariant analysis of the patients with prostate cancer.
Age 50 y Age> 50 y p
Patients (n) 26 108
Age (y) 47.0± 2.7 75.13± 8.1
DRE
Positive 8 (47%) 43 (62%) 0.191
Negative 9 (53%) 26 (38%)
TRUS prostate volume (mL) 29.33± 10.0 37.10± 17.9 0.122
PSA (ng/mL) 0.847
<4 0 (0%) 5 (6%)
4e10 7 (32%) 25 (32%)
10e20 5 (23%) 18 (23%)
>20 10 (45%) 30 (39%)
Initial presentation 0.011
LUTS 7 (29%) 50 (63%)
Incidental finding 9 (38%) 10 (13%)
Bone pain 3 (13%) 3 (4%)
Hematuria 3 (13%) 5 (6%)
Dysuria 2 (7%) 3 (4%)
AUR 0 (0%) 5 (6%)
Others 0 (0%) 3 (4%)
Stage 0.652
I 0 (0%) 5 (6%)
II 14 (56%) 38 (48%)
III 4 (16%) 13 (17%)
IV 7 (28%) 23 (29%)
Risk classificationa 0.678
Low 2 (12%) 17 (22%)
Intermediate 7 (44%) 29 (37%)
High 7 (44%) 33 (42%)
Treatmentb 0.001
Surgery 13 (59%) 14 (18%)
Nonsurgery 9 (41%) 62 (82%)
AUR ¼ acute urinary retention; DRE ¼ digital rectal examination; LUTS ¼
lower urinary tract symptoms; PSA ¼ prostate-specific antigen; TRUS ¼
tracsrectal ultrasound.
a According to D'amico risk classification, for localized disease or locally
advanced disease. Metastatic disease not included.
b Nonsurgery group includes hormone deprivation therapy, radiotherapy,
watchful waiting, and active surveillance.
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Several studies reported a better survival outcome in men
younger than 50 years of age.4,5 However, others have
revealed no significant difference in disease recurrence, his-
tological grade, and disease stage.6e9 We retrospectively
evaluated the clinical behavior, pathological characteristics
and prognosis of prostate cancer in men younger than 50 years
of age.
2. Methods
We retrospectively reviewed the Taipei Veterans General
Hospital cancer registry, examining the charts of patients with
prostate cancer between January 1997 and December 2013
whose age at diagnosis was younger than 50 years. All patients
who were diagnosed or treated at our hospital were included in
this study.
Demographic data, symptoms at initial presentation, his-
tological grade, clinical or pathological stage, initial
prostate-specific antigen (PSA) level on diagnosis, prostate
volume on transrectal ultrasound, treatment, and clinical
outcome were all recorded. Patients with nonadenocarcinoma
condition or inadequate medical records data were excluded.
For disease stage analysis, pathological stage was used when
available; otherwise, clinical stage was used. The disease
stage was assessed according to the AJCC (American Joint
Committee on Cancer) (2010) tumorenodeemetastasis sys-
tem. Histological grade was defined as Gleason score in the
following manner: low grade (score 2e5), intermediate grade
(score 6e7), and high grade (score 8e10). Symptoms on
initial presentation were categorized into seven groups as
follows: lower urinary tract symptoms (LUTS), incidental
finding, bone pain, hematuria, dysuria, acute urinary reten-
tion, and others. The LUTS consisted of a feeling of
incomplete bladder emptying, frequency, intermittency, ur-
gency, weak stream, straining, and nocturia. Patients who
survived without evidence of disease, or who were lost to
follow-up, were censored. Survival was defined as the time
from initial presentation to the study end point, including
death or censoring.
A patient group comprising study participants older than 50
years was selected for comparison with the younger patients.
There were 106 patients randomly selected with a confidence
level of 95% and a confidence interval of 9.4%.
Differences in the distribution of demographic, clinical,
and pathological variables, such as symptoms of presenta-
tion, PSA level, D'Amico risk classification, and disease
stage, between younger and older men were evaluated using
Fisher's exact test. The difference of prostate volume was
assessed by use of the t test. Survival curves were plotted
using the KaplaneMeier method, with statistical signifi-
cance calculated according to the log-rank test. Data were
analyzed using IBM SPSS Statistics 20.0 (IBM, Armonk,
NY, USA). A p value < 0.05 was considered statistically
significant.
We informed the patients about the study, and consent was
obtained from each patient.3. Results
A total of 4716 patients were diagnosed with prostate cancer
in the 17-year period, and 29 patientswere younger than 50 years
of age. Of 29 prostate cancer cases identified, 26 had patholog-
ical diagnosis of adenocarcinoma, which accounted for 0.55%of
all patients. The other three had the pathological diagnosis
including embryonal rhabdomyosarcoma and stromal sarcoma.
The mean age of the patients at initial diagnosis was 46.8± 2.8
years (range, 39e50 years). The median follow-up duration was
79.6 months (range, 4.5e198.2 months). The average prostate
volume on transrectal ultrasound was 29.33± 10.0 mL. Nine
patients were positive and eight were negative on digital rectal
examination. The most common presenting symptoms were
incidental findings in nine patients (38%), LUTS in seven (29%),
bone pain in three (13%), and hematuria in three (13%) (Table 1).
Additionally, six of 26 patients (23%) had a family history of
prostate cancer in our study group.
Of those 26 patients, cancer staging was as follows: Stage I
(n¼ 0, 0%), Stage II (n¼ 14, 56%), Stage III (n¼ 4, 16%),
Fig. 2. Stage-specific overall survival rate in patients with Stage II prostate
cancer ( p ¼ 0.394).
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revealed one patient (4%) with low grade, 18 patients (72%)
with intermediate grade, and six patients (24%) with high
grade (Table 1). Furthermore, 13 of the 26 patients underwent
surgical management of radical prostatectomy, and nine pa-
tients underwent nonsurgical management, including hormone
deprivation therapy and/or radiotherapy (Table 1).
Compared with older patients with prostate adenocarci-
noma, patients younger than 50 years of age had lower digital
rectal examination positive rate (47% vs. 62%, p¼ 0.191) and
smaller prostate volume on transrectal ultrasound
(29.33 ± 10.0 mL vs. 37.10± 17.9 mL, p¼ 0.122), but both
were not statistically significant. Distribution of PSA on initial
diagnosis showed no significant difference (Table 1). For the
initial presentation, the majority of older patients presented
with LUTS. Nevertheless, more patients were incidentally
found to have prostate cancer in the younger patients group
without obvious voiding symptoms. Other symptoms,
including bone pain, hematuria, and dysuria, accounted for a
relatively small proportion of the patients' initial symptoms.
The distribution difference was statistically significant
( p¼ 0.011; Table 1).
For cancer staging and tumor grading, most patients pre-
sented with Stage II disease as well as an intermediate risk
group on D'Amico classification.10 No significant difference
was observed between the two groups (Table 1). Patients
younger than 50 years of age mostly underwent radical pros-
tatectomy. The older patients were more frequently treated
with nonsurgical intervention, including hormone deprivation
therapy, radiotherapy, watchful waiting, or active surveillance
(Table 1).
KaplaneMeier survival curves revealed no overall survival
difference between the younger and older patients ( p¼ 0.454;
Fig. 1). No significant difference could be demonstrated be-
tween the two groups in stage-specific survival (Figs. 2 and 3).
Biochemical-free survival, which was evaluated in patients
who underwent curative treatment, i.e., radical prostatectomy
or curative radiotherapy with or without androgen deprivationFig. 1. Overall survival rate according to age ( p ¼ 0.454).
Fig. 3. Stage-specific overall survival rate in patients with Stage IV prostate
cancer ( p ¼ 0.735).therapy, revealed no significant difference between the two age
groups ( p¼ 0.960; Fig. 4). Patients with Stage I and Stage III
diseases have 100% survival during the follow-up period in
both age groups; therefore, they are not shown in the survival
analysis. For different treatment modalities, neither surgical
nor nonsurgical intervention revealed a significant difference
in overall patient survival (Fig. 5). Patients who underwent
radical prostatectomy had 100% survival in both age groups,
and are also not shown in the survival analysis.
4. Discussion
Prostate cancer has been infrequently reported in men
younger than 50 years of age. Review of the literature shows
that prostate cancer traditionally occurs in approximately 1%
Fig. 4. Biochemical-free survival according to age ( p ¼ 0.960).
Fig. 5. Overall survival rate in patient who underwent nonsurgical treatment ( p
¼ 0.395).
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patients younger than 50 years accounted for 0.55% of all
patients with prostate cancer, which was less than described in
the previous reports. It has been estimated that approximately
43% of early onset disease (in those younger than 55 years) is
of the inherited form of prostate cancer,9 whereas in the pre-
sent series we found that 23% of patients have a family history
of prostate cancer.
Existing reports provide conflicting views regarding the
clinical characteristics of prostate cancer in young men. Tja-
den et al2 reported their experience with 56 patients younger
than 50 years and observed a very poor clinical outcome.
Johnson et al3 observed the same biologic aggressiveness of
prostate cancer in 26 patients younger than 50 years. Other
researchers, however, have not observed the same findings.Byar and Mostofi4 reviewed 51 cases and reported that
younger men may have a better prognosis. Silber and
McGavran5 observed favorable survival rates in men younger
than 50 years. Benson et al6 reported their experience with 14
patients aged 45 years or younger with prostate cancer, which
revealed similar outcomes as in the older population. Huben
et al7 reported data from the American College of Surgeons
National Survey, which demonstrated 168 patients younger
than 50 years diagnosed with prostate cancer prior to 1975.
The data suggested no significant differences in survival by
cancer stage when compared with older men. The most recent
series was reported by Werthman et al,8 examining 20 patients
younger than 50 years of age. In that investigation, the authors
observed in younger men a similar presentation and clinical
course as found in older men. Aprikian et al9 reported a series
of 151 patients younger than 50 years with prostate cancer and
revealed similar symptomatology, histologic grade, and dis-
ease stage between the younger and older populations. The
existing literature demonstrates a high level of discrepancy on
this issue, and Byar and Mostofi4 supposed that the impression
of poor outcome in younger men may in fact result from the
psychological effect of clinicians. And there are few studies
available focusing on treatment and outcomes in these specific
patient groups. Smith et al11 reported that patients 50 years or
younger undergoing radical prostatectomy have a more
favorable disease-free outcome.
Populations included in the reported English literature
primarily consisted of races derived from Western countries.
There was sparse English-language literature regarding Asian
young men with prostate adenocarcinoma. In the present
study, our result revealed that patients younger than 50 years
had similar risk classification, disease stage, and PSA level as
the older population. However, patients younger than 50 years
with prostate cancer less frequently presented with initial
symptoms of LUTS. Therefore, urologists must bear in mind
that prostate cancer should be one of the several differential
diagnoses in young patients who present with any abnormal
urinary tract symptoms.
There are several limitations in this study. The major
limitation is that our research involved a single institution
database and retrospective recruitment. A total of 26 patients
were included, which represents a relatively small sample
size. Some patients had short follow-up duration (less than 3
years). The short follow-up duration may be inadequate to
reflect the actual disease characteristics. Owing to the above
reasons, some subgroups could not demonstrate survival
variation sufficiently for the purpose of analysis. In the future,
it would be beneficial for additional studies to involve mul-
tiple centers as well as a longer follow-up period for further
investigation.
In conclusion, our experience showed that patients younger
than 50 years had similar histological grade, disease stage,
PSA level, disease stage, overall survival, and biochemical-
free survival as the older population. However, patients
younger than 50 years with prostate cancer less frequently
presented with initial symptoms of LUTS.
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